Fig. 1: Potential clinical consequences of COVID-19-associated coagulopathy. | Nature Reviews Immunology

Fig. 1: Potential clinical consequences of COVID-19-associated coagulopathy.

From: Understanding COVID-19-associated coagulopathy

Fig. 1: Potential clinical consequences of COVID-19-associated coagulopathy.

COVID-19-associated coagulopathy (CAC) is characterized by coagulation disorders that affect multiple tissue and organ sites, and vary from skin purpura (also known as ‘COVID toe’) to myocardial infarction and neurological dysfunction. Circulating microthrombi and/or macrothrombi can lead to multi-organ injury or failure.

Back to article page